TCRT Stock Soars As Velaris Deal Transforms Alaunos

Alaunos Therapeutics Inc. stocks have been trading up by 19.42 percent amid heightened optimism over its cancer therapy pipeline.

Live Update At 08:31:58 EDT: On Wednesday, October 14, 2026 Alaunos Therapeutics Inc. stock [NASDAQ: TCRT] is trending up by 19.42%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

TCRT just flipped its chart from grind‑down biotech to full‑blown momentum story. For weeks, Alaunos Therapeutics traded mostly between $0.78 and $1.30, with fading volume and little excitement. Then on 2026/10/12, TCRT closed at $1.05. One day later, after the Velaris deal and $350M raise, the stock opened at $1.73, ripped to $4.32, and closed at $3.03. That is a massive repricing in a single session.

Intraday, TCRT’s 5‑minute chart shows wild swings between $3.10 and $4.17, with constant back‑and‑forth action. This is classic high‑volatility trading territory. For short‑term traders, Alaunos Therapeutics now behaves more like a momentum small cap than a sleepy micro‑cap.

Fundamentals still reflect an early‑stage biotech. Recent quarterly revenue sits around $5,000, essentially pre‑commercial. Losses are steep, with a pretax profit margin near ‑3,348% and negative cash flow of about ‑$300,000 for the quarter. TCRT’s current ratio of 0.8 and working capital deficit show why that $350M financing matters. Without it, Alaunos Therapeutics was tight on cash. With it, traders now see a multi‑year runway and a very different risk profile.

Why Traders Are Watching TCRT After The Velaris Deal

The reason TCRT exploded is simple: story plus funding. Alaunos Therapeutics didn’t just announce another small trial tweak. It closed the acquisition of Velaris Therapeutics, instantly adding a pipeline of ActRII‑Fc ligand traps and biologics aimed at pulmonary arterial hypertension and related cardiopulmonary diseases. In biotech, a credible new pipeline can reset how the market values a company overnight. That is what traders are betting on with TCRT.

At the same time, Alaunos Therapeutics locked in about $350M via a private placement of Series C non‑voting convertible preferred stock. The new capital is expected to fund operations into 2029 and carry several programs through proof‑of‑concept and early regulatory filings. For a micro‑cap like TCRT, that is huge. Cash risk is one of the biggest overhangs in small biotech names. When a company extends runway by multiple years in one shot, traders often treat that as a major de‑risking event.

The market reaction backs that up. Alaunos Therapeutics shares spiked roughly 126% to about 225% on extremely heavy volume immediately after the news. That kind of move, on that kind of volume, typically signals more than just a day‑trader squeeze. It suggests the entire market is recalibrating TCRT’s future. VLR199 for pulmonary arterial hypertension now looks like a flagship asset, and any future data readout around it will be a major catalyst traders stalk.

For now, TCRT is a textbook momentum chart: big gap, big range, thick volume. That’s exactly the kind of setup active traders study night after night.

Conclusion

TCRT has moved from the biotech bargain bin to the front page of momentum scanners in one trading day. Alaunos Therapeutics combined a transformative acquisition of Velaris Therapeutics with a $350M private placement, stretching its cash runway into 2029 and loading its pipeline with cardiopulmonary programs, led by VLR199. On the tape, that translated into a 100%‑plus gap and intraday spikes up toward 4x the prior close, with heavy participation across the market.

For traders, the message is clear. Alaunos Therapeutics is now a catalyst‑driven name where headlines and trial updates can move the stock dollars, not pennies. The fundamentals still show a tiny revenue base, negative earnings, and historically thin liquidity, but the new funding changes the survival math. TCRT now has time to chase proof‑of‑concept instead of worrying about the next small raise.

That does not mean the risk is gone. Biotech trial setbacks, dilution from preferred stock, and sentiment shifts can all crush a parabolic chart. As Tim Sykes loves to say, “Cut losses quickly — always protect your account so you can trade again tomorrow.” As millionaire penny stock trader and teacher Tim Sykes, says, “You must adapt to the market; the market will not adapt to you.”. With Alaunos Therapeutics, the opportunity is big, but so is the volatility. Traders who respect their plans, study the chart, and treat TCRT as a trading vehicle — not a long‑term promise — will be best positioned to learn from this wild move.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

• Penny Stocks Trading Guide
• Best Penny Stocks Under $1 to Buy Today
• Top 8 Penny Stocks to Watch on Robinhood

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks